First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non–small-cell lung cancer: the TORCH randomized trial

C Gridelli, F Ciardiello, C Gallo, R Feld… - Journal of Clinical …, 2012 - ascopubs.org
Purpose Erlotinib prolonged survival of unselected patients with advanced non–small-cell
lung cancer (NSCLC) who were not eligible for further chemotherapy, and two phase II …
被引用次数：276 相关文章
[PDF] academia.edu

[PDF][PDF] First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial

C Gridelli, F Ciardiello, C Gallo, R Feld, C Butts… - 2012 - academia.edu
Purpose Erlotinib prolonged survival of unselected patients with advanced non–small-cell
lung cancer (NSCLC) who were not eligible for further chemotherapy, and two phase II …
[PDF] publicationslist.org

[PDF][PDF] First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial

C Gridelli, F Ciardiello, C Gallo, R Feld, C Butts… - 2012 - publicationslist.org
Purpose Erlotinib prolonged survival of unselected patients with advanced non–small-cell
lung cancer (NSCLC) who were not eligible for further chemotherapy, and two phase II …
[PDF] psu.edu

[PDF][PDF] First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial

C Gridelli, F Ciardiello, C Gallo, R Feld, C Butts… - 2012 - Citeseer
Purpose Erlotinib prolonged survival of unselected patients with advanced non–small-cell
lung cancer (NSCLC) who were not eligible for further chemotherapy, and two phase II …

First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial

C Gridelli, F Ciardiello, C Gallo, R Feld… - JOURNAL OF …, 2012 - iris.unicampania.it
Purpose: Erlotinib prolonged survival of unselected patients with advanced non–small-cell
lung cancer (NSCLC) who were not eligible for further chemotherapy, and two phase II …

First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial

C Gridelli, F Ciardiello, C Gallo… - Journal of clinical …, 2012 - pubmed.ncbi.nlm.nih.gov
Purpose Erlotinib prolonged survival of unselected patients with advanced non-small-cell
lung cancer (NSCLC) who were not eligible for further chemotherapy, and two phase II …

[引用][C] First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial.

C Gridelli, F Ciardiello, C Gallo, R Feld, C Butts… - JOURNAL OF …, 2012 - iris.unito.it
[PDF] unife.it

[PDF][PDF] First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial

C Gridelli, F Ciardiello, C Gallo, R Feld, C Butts… - J Clin Oncol, 2012 - iris.unife.it
Purpose Erlotinib prolonged survival of unselected patients with advanced non–small-cell
lung cancer (NSCLC) who were not eligible for further chemotherapy, and two phase II …

First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: The TORCH randomized trial

C Gridelli, F Ciardiello, C Gallo, R Feld, C Butts… - JOURNAL OF …, 2012 - air.unimi.it
Purpose: Erlotinib prolonged survival of unselected patients with advanced non-small-cell
lung cancer (NSCLC) who were not eligible for further chemotherapy, and two phase II …

[引用][C] First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non―Small-Cell Lung Cancer: The TORCH Randomized Trial

C GRIDELLI, F CIARDIELLO, N LEIGHL… - Journal of clinical …, 2012 - pascal-francis.inist.fr
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced
Non―Small-Cell Lung Cancer: The TORCH Randomized Trial CNRS Inist Pascal-Francis CNRS …